Difference between revisions of "Mepolizumab (Nucala)"
Jump to navigation
Jump to search
m (Jwarner moved page Mepolizumab (Bosatria) to Mepolizumab (Nucala): FDA approval under a different brand name) |
m |
||
Line 1: | Line 1: | ||
− | =General information= | + | ==General information== |
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). | ||
− | = | + | ==Diseases for which it is used== |
+ | *[[Hypereosinophilic syndrome (HES)]] | ||
− | == | + | ==History of changes in FDA indication== |
− | + | ''No approval for hematology/oncology conditions, at this time.'' | |
− | + | ||
+ | ==Also known as== | ||
+ | *'''Brand names:''' Bosatria, Nucala | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
− | [[Category: | + | [[Category:Intravenous medications]] |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-IL-5 antibodies]] | [[Category:Anti-IL-5 antibodies]] | ||
− | [[Category: | + | [[Category:Hypereosinophilic syndrome medications]] |
+ | |||
+ | [[Category:FDA approved in 2015]] |
Revision as of 02:30, 12 August 2018
General information
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5).
Diseases for which it is used
History of changes in FDA indication
No approval for hematology/oncology conditions, at this time.
Also known as
- Brand names: Bosatria, Nucala